Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD

Rick Hodder, Demetri Pavia, Angela Lee, Eric Bateman, Rick Hodder, Demetri Pavia, Angela Lee, Eric Bateman

Abstract

Bronchoconstriction has been reported in asthma and chronic obstructive pulmonary disease (COPD) patients after administration of some aqueous inhalation solutions. We investigated the incidence of this event during long-term clinical trials of tiotropium delivered via Respimat(®) Soft Mist™ Inhaler (SMI). We retrospectively analyzed pooled data from two identical Phase III clinical trials, in which 1990 patients with COPD received 48 weeks' treatment with once-daily tiotropium (5 or 10 μg) or placebo inhaled via Respimat(®) SMI. We recorded the incidence of bronchospasm and of a range of respiratory events that could suggest bronchoconstriction during the first 30 minutes after inhalation of study treatment on each of the eight test days. No patients reported bronchospasm. Six patients (0.3%) reported a combination of at least two events suggestive of bronchoconstriction, and 21 (1.1%) reported either rescue medication use or a respiratory adverse event. Asymptomatic falls in forced expiratory volume in one second (FEV(1)) of ≥15% were recorded on all test days, with no change in incidence over time, and affected 8.2% of those in the tiotropium groups and 14.5% of those on placebo. In COPD patients receiving long-term treatment with tiotropium 5 or 10 μg via Respimat(®) SMI, no bronchospasm was recorded, and the number of events possibly indicative of paradoxical bronchoconstriction was very low.

Trial registration: ClinicalTrials.gov NCT00168831 NCT00168844.

Keywords: COPD; bronchoconstriction; inhalation device; tiotropium.

Figures

Figure 1
Figure 1
Proportion of patients (%) with respiratory events suggestive of administration-related bronchoconstriction during the 30 minutes immediately after inhalation of study treatment on each test day. Events are shown by treatment for Categories B–D (no Category A events occurred), and patients are grouped according to the worst category of event experienced. The number of patients tested on each day fell as the study progressed (see Table 4). See text for definition of categories.

References

    1. Dalby R, Spallek M, Voshaar T. A review of the development of Respimat® Soft Mist™ Inhaler. Int J Pharm. 2004;283:1–9.
    1. Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist™ Inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18:273–282.
    1. Newman SP. Use of gamma scintigraphy to evaluate the performance of new inhalers. J Aerosol Med. 1999;12(Suppl 1):S25–S31.
    1. Kilfeather SA, Ponitz HH, Beck E, Schmidt P, Lee A, Bowen I, et al. Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft Mist™ Inhaler in patients with COPD. Respir Med. 2004;98:387–397.
    1. Von Berg A, Jeena PM, Soemantri PA, et al. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat® Soft Mist™ inhaler versus a conventional metered dose inhaler plus spacer in children with asthma. Pediatr Pulmonol. 2004;37:264–272.
    1. Beasley CRW, Rafferty P, Holgate ST. Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution [letter] BMJ. 1987;294:1197–1198.
    1. Cocchetto DM, Sykes RS, Spector S. Paradoxical bronchoconstriction after use of inhalation aerosols: a review of the literature. J Asthma. 1991;28:49–53.
    1. Nicklas RA. Paradoxical bronchospasm associated with the use of inhaled beta agonists. J Allergy Clin Immunol. 1990;85:959–964.
    1. Yarbrough J, Mansfield LE, Ting S. Metered-dose inhaler induced bronchospasm in asthmatic patients. Ann Allergy. 1985;55:25–27.
    1. Pavia D, Moonen D. Preliminary data from phase III studies with Respimat, a propellant-free soft mist inhaler. J Aerosol Med. 1999;12(Suppl 1):S33–S39.
    1. Suzuki S, Miyashita A, Matsumoto Y, Okubo T. Bronchoconstriction induced by spirometric manoeuvres in patients with bronchial asthma. Ann Allergy. 1990;65:315–320.
    1. Mackay AD, Mustchin CP, Sterling GM. The response of asthmatic patients and normal subjects to maximum respiratory manoeuvres. Spirometry-induced bronchoconstriction. Eur J Respir Dis Suppl. 1980;106:35–40.
    1. Roncoroni AJ, Goldman E, Puy RJ, Mancino M. Bronchoconstriction induced by repeated forced vital capacity manoeuvres. Acta Allergol. 1975;30:375–389.
    1. Rafferty P, Beasley R, Holgate ST. Comparison of the efficacy of preservative free ipratropium bromide and Atrovent nebuliser solution. Thorax. 1988;43:446–450.
    1. Koehler D, Pavia D, Dewberry H, Hodder R. Low incidence of paradoxical bronchoconstriction with bronchodilator drugs administered by Respimat® Soft Mist™ Inhaler: results of Phase II single-dose crossover studies. Respiration. 2004;71:469–476.
    1. Hodder R, Pavia D, Dewberry H, et al. Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat® Soft Mist™ Inhaler. Respir Med. 2005;99:1087–1095.
    1. Leclerc V, Lafferre M, Pavia D. Acute local tolerability of acidic aqueous vehicles delivered via Respimat® Soft Mist™ Inhaler in hyperreactive asthma patients. Respiration. 2007;74:691–696.
    1. Patel KR, Pavia D, Lowe L, Spiteri M. Inhaled ethanolic and aqueous solutions via Respimat Soft Mist Inhaler are well-tolerated in asthma patients. Respiration. 2006;73:434–440.
    1. Bateman E, Singh D, Smith D, et al. Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomised studies. Int J Chron Obstruct Pulmon Dis. 2010;5:197–208.
    1. Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of Respimat with conventional metered-dose inhalers with and without spacer devices. Chest. 1998;113:957–963.
    1. Shaheen MZ, Ayres JG, Benincasa C. Incidences of acute decreases in peak expiratory flow following the use of metered-dose inhalers in asthmatic patients. Eur Respir J. 1994;7:2160–2164.
    1. Huchon G, Hofbauer P, Cannizzaro G, Iacono P, Wald F. Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO. Eur Respir J. 2000;15:663–669.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi